Intellia Therapeutics, Inc. (38I.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 08:14AM CEST. Market open.
| Previous Close | 23.58 |
| Open | 23.11 |
| Bid | 23.10 x 25000 |
| Ask | 23.90 x 25000 |
| Day's Range | 23.11 - 23.11 |
| 52 Week Range | 18.46 - 43.01 |
| Volume | |
| Avg. Volume | 159 |
| Market Cap | 2.23B |
| Beta (5Y Monthly) | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
- Simply Wall St.
It Looks Like Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights Intellia Therapeutics will host its Annual General Meeting on 12th of June CEO John Leonard's total...
- Zacks
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
© 2024 Yahoo. All rights reserved.